Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2016 Dec 2;11(12):e0166942. doi: 10.1371/journal.pone.0166942

Uptake of Community-Based Peer Administered HIV Point-of-Care Testing: Findings from the PROUD Study

Lisa Lazarus 1,*, Sheetal Patel 1, Ashley Shaw 1, Sean Leblanc 2,3, Christine Lalonde 2, Manisha Hladio 4, Kira Mandryk 5, Cynthia Horvath 5, William Petrcich 1, Claire Kendall 1,6, Mark W Tyndall 1,7; for the Proud Community Advisory Committee
Editor: Kathy Petoumenos8
PMCID: PMC5135055  PMID: 27911908

Abstract

Objectives

HIV prevalence among people who inject drugs (PWID) in Ottawa is estimated at about 10%. The successful integration of peers into outreach efforts and wider access to HIV point-of-care testing (POCT) create opportunities to explore the role of peers in providing HIV testing. The PROUD study, in partnership with Ottawa Public Health (OPH), sought to develop a model for community-based peer-administered HIV POCT.

Methods

PROUD draws on community-based participatory research methods to better understand the HIV risk environment of people who use drugs in Ottawa. From March-October 2013, 593 people who reported injecting drugs or smoking crack cocaine were enrolled through street-based recruitment. Trained peer or medical student researchers administered a quantitative survey and offered an HIV POCT (bioLytical INSTI test) to participants who did not self-report as HIV positive.

Results

550 (92.7%) of the 593 participants were offered a POCT, of which 458 (83.3%) consented to testing. Of those participants, 74 (16.2%) had never been tested for HIV. There was no difference in uptake between testing offered by a peer versus a non-peer interviewer (OR = 1.05; 95% CI = 0.67–1.66). Despite testing those at high risk for HIV, only one new reactive test was identified.

Conclusion

The findings from PROUD demonstrate high uptake of community-based HIV POCT. Peers were able to successfully provide HIV POCT and reach participants who had not previously been tested for HIV. Community-based and peer testing models provide important insights on ways to scale-up HIV prevention and testing among people who use drugs.

Introduction

Despite major gains in HIV prevention, treatment and care, uptake among people who use drugs (PWUD) remains inequitable [1]. HIV testing among at-risk groups is central to HIV prevention efforts, in particular as the ‘treatment as prevention’ paradigm has been shown to improve health outcomes and longevity among those infected, to prevent onward HIV transmission, and to reduce healthcare costs [25]. However, PWUD are more likely to receive HIV testing later in the course of infection and some only after developing HIV-related opportunistic infections [6]. This disparity to accessing conventional HIV testing services among PWUD reflects the structural, economic, social, and individual-level barriers experienced by this population [6], including perceived and enacted stigma by health care providers [7].

The recent availability of rapid HIV point-of-care testing (POCT) offers new strategies for improving the uptake of testing among PWUD in both clinical and community-based settings [8,9]. Rapid HIV POCT can reduce anxiety associated with waiting for test results: non-reactive results can be provided at the time of testing, while participants with reactive results can receive on-the-spot linkages to confirmatory testing, support, and treatment [10]. Community-based POCT offers the additional advantage of reaching high risk populations who might not otherwise seek care [11], especially if peers are incorporated into service delivery [6]. Training peer leaders who use (and continue to use) drugs as HIV educators has been shown to be an effective mechanism for HIV prevention among PWUD [1216]. Furthermore, peer-delivery of testing has been delivered within communities of men who have sex with men (MSM) [11,17,18] and among PWUD with high levels of satisfaction and comfort with confidentiality [19].

The city of Ottawa, Ontario has a large network of people who use both injection and non-injection drugs for a city of its size [2022]. Despite declines in HIV incidence among the general population, HIV rates among people who use injection drugs in Ottawa remain disproportionately high, with an estimated prevalence of 10% [21]. As 43% of PWUD who were diagnosed with HIV report sharing drug use equipment [21], ongoing transmission remains a significant concern. The PROUD Study is a community-based research project that arose in response to the high rates of HIV among PWUD in Ottawa. In this study, we report a novel community-based peer-administered POCT program developed in collaboration with the local public health authority and communities of PWUD. To the best of our knowledge, and with the exception of the integration of peer educators and testers in a pilot project in Vancouver’s Downtown Eastside [19], there are no other examples of engaging PWUD as testers in community-based HIV testing. Our objective was to elicit the factors associated with the uptake of community-based HIV POCT and to inform models of peer-administered testing among this population.

Methods

Study Design

The Participatory Research in Ottawa: Understanding Drugs (PROUD) Study is a prospective cohort study examining HIV risk among people who use drugs in Ottawa, Ontario and has been described elsewhere [23]. Briefly, between March and December 2013, eligible and consenting participants completed a one-time interviewer-administered iPad-based questionnaire, followed by an opt-in HIV POCT. The quantitative survey included individual-level variables, including socio-demographic information and drug use patterns; interpersonal variables, including sexual history and connections to community; and structural variables, including access and use of harm reduction services, information on housing and homelessness, experiences with the law, and health status and access to health care, including hepatitis C virus (HCV) and HIV testing and treatment. Interviews were administered by a peer or medical student/community ally, depending on interviewer availability and participant comfort. All interviewers received comprehensive training in research ethics, including confidentiality and privacy, and interviewing skills. A cash honorarium (CAN $20.00) was offered after survey completion regardless of whether participants chose to opt-in to HIV POCT.

Study Participants

As previously described in detail [23], potential participants were recruited through peer-based purposive recruitment on the streets and in social service settings frequented by PWUD. Interviews were conducted at our research site, located in Ottawa’s downtown Byward Market area. The space, rented for the purpose of this study, used to be a drop-in centre and was therefore well-known to the community and centrally located. Eligibility criteria included age 16 years or older, having injected or smoked drugs other than marijuana in the past 12 months, and having lived in Ottawa for at least three months.

POCT Intervention

Interviewers (eleven peers, fifteen medical students, and three community allies) received HIV POCT (bioLytical INSTI test) training and certification by Ottawa Public Health. Training included sessions on the following topics: therapeutic relationships and confidentiality, HIV 101, infection control and quality assurance, performing the POCT and result interpretation, and pre- and post-test counseling (including role playing and debriefing). A public health nurse with harm reduction experience was onsite to assist with pre- and post-test counseling, conducting the POCT as well as drawing confirmatory serology for reactive or indeterminate POCT results, and to provide quality assurance, support, referrals and debriefing with peers and medical students. POCT was offered by the survey interviewer upon survey completion. Participants were excluded from POCT if the public health nurse was not present, if they responded ‘yes’ to the question ‘Have you ever tested positive for HIV?’ during the interview-administered questionnaire, or if they declined for other reasons (with reason recorded by interviewers).

This study received ethical approval from The Ottawa Hospital and Ottawa Public Health Research Ethics Boards. All participants provided their written consent to participate in the study and the consent process was approved by both REBs.

Statistical Analysis

We undertook descriptive and univariate analyses [24] to examine which patient characteristics were associated with agreement to undergo HIV POCT, including: drug use patterns; injection practices; equipment sharing practices; access to health care; past experiences with HIV and HCV testing; condom use with sexual partners; sex work; housing status; and experiences with the law. The exposures of interest consisted of those study questions that the investigators and/or peers determined to be potentially associated with perceived need for testing and barriers to accessing care for PWUD. We used chi-square or Fisher exact tests as appropriate for categorical variables and the Wilcoxon rank sum test for continuous variables. Associations are presented as univariate odds ratios with corresponding 95% confidence intervals (CIs).

Results

593 participants were recruited for this analysis: 5 (0.8%) were excluded due to the unavailability of POCT and onsite nursing on the day of their interview and 38 (6.4%) were excluded because of self-reported HIV infection. Of those remaining, 550 (92.7%) were offered HIV POCT: Peers and medical student/allies offered testing to 233 (42.4%) and 317 (57.6%) participants respectively. There was no significant difference in uptake of testing between those offered a peer vs. a non-peer interviewer (83.7% vs. 83.0% respectively, OR = 1.05; 95% CI = 0.67–1.66). The most common reasons for testing refusal were no specific reason provided (n = 21, 22.8%) and recent HIV testing (n = 20, 21.7%). Among participants who consented to POCT, 74 (16.2%) reported never having previous HIV testing.

Table 1 shows the demographic and drug use characteristics of the participants by uptake of POCT. Participants who agreed to POCT were older (43 vs. 39 years, p = 0.02) and less likely to be female (OR = 0.59; 95% CI = 0.35–0.98). Participants who reported ever injecting drugs were more likely to have consented to testing (OR = 1.71 95% CI = 1.09–2.69), but there were no other significant differences in drug use characteristics between the two groups.

Table 1. Demographic and drug use characteristics associated with uptake of an HIV POCTa.

Characteristic Uptake of an HIV POCT
No. (%) of participantsb
OR (95% CI)
Yes
n = 458
No
n = 92
Agec (median, IQR) 43 (34–50) 39 (30–48) P-value = 0.02
Gender
Female 87 (77.0) 26 (23.0) 0.59 (0.35–0.98)
Male 366 (85.1) 64 (14.9) ref
Language
French 80 (81.6) 18 (18.4) 0.81 (0.45–1.44)
English 341 (84.6) 62 (15.4) ref
Education
Less than high school 228 (83.5) 45 (16.5) 1.04 (0.66–1.62)
High school and higher 230 (83.0) 47 (17.0) ref
Ethnicity
Aboriginal 84 (82.3) 18 (17.7) 0.92 (0.52–1.63)
Non-Aboriginal 374 (83.5) 74 (16.5) ref
Neighbourhood of Residence
Market 197 (81.1) 46 (18.9) 0.73 (0.46–1.16)
Other Ottawa neighbourhood 240 (85.4) 41 (14.6) ref
Sexual Identity
LGBQd 32 (74.4) 11 (25.6) 0.53 (0.25–1.09)
Heterosexual 421 (84.7) 76 (15.3) ref
Ever Injected Drugs
Yes 300 (86.0) 49 (14.0) 1.71 (1.09–2.69)
No 154 (78.2) 43 (21.8) ref
Injected Drugs in the past 12 monthse
Yes 198 (84.6) 36 (15.4) 0.65 (0.33–1.31)
No 101 (89.4) 12 (10.6) ref
Injected Cocaine
Yes 129 (84.3) 24 (15.7) 0.95 (0.45–2.01)
No 68 (85.0) 12 (15.0) ref
Injected Crack cocaine
Yes 99 (86.8) 15 (13.2) 1.38 (0.67–2.84)
No 96 (82.8) 20 (17.2) ref
Injected Opiates
Yes 156 (83.9) 30 (16.1) 0.74 (0.29–1.90)
No 42 (87.5) 6 (12.5) ref
Injected Speedball
Yes 53 (85.5) 9 (14.5) 1.11 (0.49–2.52)
No 143 (84.1) 27 (15.9) ref
Injected with other people
Yes 164 (85.9) 27 (14.1) 1.76 (0.76–4.11)
No 31 (77.5) 9 (22.5) ref
Injected in public
Yes 65 (78.3) 18 (21.7) 0.50 (0.24–1.04)
No 122 (87.8) 17 (12.2) ref
Assistance to inject
Yes 73 (82.0) 16 (18.0) 0.74 (0.36–1.52)
No 123 (86.0) 20 (14.0) ref
Used unknown needle
Yes 32 (88.9) ≤ 5 (11.1) 1.56 (0.52–4.72)
No 164 (83.7) 32 (16.3) ref
Injected with used needle
Yes 43 (84.3) 8 (15.7) 0.98 (0.42–2.31)
No 153 (84.5) 28 (15.5) ref
Ever Overdosed
Yes 193 (83.6) 38 (16.4) 1.03 (0.65–1.63)
No 261 (83.1) 53 (16.9) ref

OR = odds ratio, CI = confidence interval.

a. Percentages are calculated on the basis of the sum across each row.

b. Except where indicated otherwise. Due to ‘no answer’/missing responses, the data for some characteristics do not sum to n = 550.

c. Median age based on n = 522.

d. LGBQ stand for Lesbian, Gay, Bisexual and Queer.

e. All drug use behaviour variables are reported for the previous 12 months unless otherwise specified.

Table 2 presents health status and access to health and harm reduction services among those who agreed and did not agree to HIV POCT. No significant differences were found between the two groups.

Table 2. Health characteristics and access to health and harm reduction services associated with uptake of an HIV POCTa.

Characteristic Uptake of an HIV POCT
No. (%) of participantsb
OR (95% CI)
Yes
n = 458
No
n = 92
Ever trouble accessing new needles
Yes 33 (84.6) 6 (15.4) 0.96 (0.37–2.50)
No 171 (85.1) 30 (14.9) ref
Accessed addiction treatment past 12 months
Yes 174 (86.1) 28 (13.9) 1.36 (0.84–2.22)
No 278 (82.0) 61 (18.0) ref
Ever received support from a peer worker
Yes 182 (85.4) 31 (14.6) 1.29 (0.80–2.07)
No 273 (82.0) 60 (18.0) ref
Ever received support from other organizations
Yes 273 (84.0) 52 (16.0) 1.10 (0.69–1.73)
No 182 (82.7) 38 (17.3) ref
Attempted suicide past 12 months
Yes 39 (95.1) ≤ 5 (4.9) 4.00 (0.95–16.87)
No 410 (83.0) 84 (17.0) ref
Sought care for health issue in past 12 months
Yes 270 (85.4) 46 (14.6) 1.42 (0.90–2.23)
No 186 (80.5) 45 (19.5) ref
Sought care from a hospital or ER in past 12 months
Yes 183 (86.7) 28 (13.3) 1.35 (0.71–2.58)
No 87 (82.9) 18 (17.1) ref
Have regular doctor
Yes 243 (85.6) 41 (14.4) 1.38 (0.88–2.18)
No 214 (81.1) 50 (18.9) ref
Ever tested for HCV
Yes 378 (84.4) 70 (15.6) 1.18 (0.63–2.22)
No 64 (82.0) 14(18.0) ref
Result of last HCV test
Positive 160 (86.0) 26 (14.0) 1.28 (0.75–2.18)
Negative 193 (82.8) 40 (17.2) ref
Know that can be charged for not disclosing HIV status to partners
Yes 397 (83.4) 79 (16.6) 1.04 (0.53–2.03)
Other (No, Maybe, Don’t know) 58 (82.9) 12 (17.1) ref
Ever tested for HIV
Yes 369 (82.2) 80 (17.8) 0.62 (0.31–1.26)
No 74 (88.1) 10 (11.9) ref
Tested for HIV in the past 12 months
Yes 187 (82.7) 39 (17.3) 1.06 (0.63–1.77)
No 145 (81.9) 32 (18.1) ref
Worried about HIV exposure
Yes 191 (85.7) 32 (14.3) 1.37 (0.85–2.21)
No 239 (81.3) 55 (18.7) ref
Who administered HIV test
Peer 195(83.7) 38 (16.3) 1.05 (0.67–1.66)
Other (medical student, nurse, RA) 263 (83.0) 54 (17.0) ref

OR = odds ratio, CI = confidence interval

a. Percentages are calculated on the basis of the sum across each row

b. Except when indicated otherwise. Due to ‘no answer’/missing responses, the data for some characteristics do not sum to n = 550.

Table 3 shows variables related to structural risks including associations with the law, sex work, and housing status. Participants who reported having engaged in sex work in the past 12 months were significantly less likely to agree to HIV POCT (OR = 0.48; 95% CI = 0.25–0.92), whereas participants who reported having spent overnight or longer in jail in the past 12 months or to have consumed drugs in jail were significantly more likely to agree to testing (OR = 1.71; 95% CI = 1.05 to 2.78) and (OR = 2.43; 95% CI = 1.07–5.52), respectively.

Table 3. Legal system encounters, sex work, and housing characteristics associated with uptake of an HIV POCTa.

Characteristic Uptake of an HIV POCT
No. (%) of participantsb
OR (95% CI)
Yes
n = 458
No
n = 92
Sex partner in past 12 months
Yes 338 (84.9) 60 (15.1) 1.37 (0.84–2.25)
No 115 (80.4) 28 (19.6) ref
Condom use in past 12 months
Not always 223 (85.4) 38 (14.6) 1.12 (0.36–3.44)
Always 21 (84.0) ≤ 5 (16.0) ref
Gave drugs, $, gifts for sexc
Yes 63 (85.1) 11(14.9) 1.02 (0.41–2.52)
No 62 (84.9) 11 (15.1) ref
Engaged in sex work
Yes 44 (74.6) 15 (25.4) 0.48 (0.25–0.92)
No 343 (86.0) 56 (14.0) ref
Current place of residence
Unstably housed 277 (82.2) 60 (17.8) 0.80 (0.50–1.28)
Stably housed 179 (85.2) 31 (14.8) ref
Ever been homeless
Yes 405 (83.2) 82 (16.8) 0.85 (0.41–1.80)
No 52 (85.3) 9 (14.7) ref
Homeless for at least one night in past 12 months
Yes 345 (85.5) 68 (16.5) 1.08 (0.65–1.80)
No 113 (82.5) 24 (17.5) ref
Ever redzonedd
Yes 177 (85.1) 31 (14.9) 1.21 (0.75–1.95)
No 278 (82.5) 59 (17.5) ref
Stopped/searched by police
Yes 302 (84.1) 57 (15.88) 1.09 (0.68–1.76)
No 155 (82.9) 32 (17.1) ref
Kept overnight or longer in jail
Yes 202 (87.8) 28 (12.2) 1.71 (1.05–2.78)
No 253 (80.8) 60 (19.2) ref
Consumed drugs in jail
Yes 116 (92.1) 10 (7.9) 2.43 (1.07–5.52)
No 86 (82.7) 18 (17.3) ref

OR = odds ratio, CI = confidence interval.

a. Percentages are calculated on the basis of the sum across each row.

b. Except where indicated otherwise. Because of ‘no answer’/missing responses, the data for some characteristics do not sum to n = 550.

c. Variables are reported for the previous 12 months unless otherwise specified.

d. Redzones were defined as any geographical area or neighborhood where law enforcement had restricted the participant’s movement.

Only one POCT resulted as reactive and was subsequently confirmed as HIV positive with confirmatory serology.

Discussion

This study demonstrates the high uptake of a community-based HIV POCT model for PWUD. In order to optimally reach people who use drugs with HIV prevention efforts, our findings support the expansion of novel community-based methods for providing testing, including peer-administered approaches. To the best of our knowledge, and with the exception of the integration of peer educators and testers in a pilot project in Vancouver’s Downtown Eastside [19], there are no other examples of engaging PWUD as testers in community-based HIV testing.

We found no difference in uptake of testing when HIV POCT was offered by a peer versus a non-peer interviewer, supporting previous work demonstrating that people at risk may be comfortable with having POCT administered by peers in a community setting. As has been demonstrated among MSM communities [11], peer testers in our study were able to handle tests, deliver non-reactive results, and provide pre- and post-test counseling in a manner that resonated with participants. Onsite nursing supervision provided peers with support for all aspects of HIV POCT, including: prompting on the POCT process; completing documentation; and guidance to identify when nurse involvement was appropriate. Furthermore, we successfully reached participants who had not previously been tested for HIV, thus providing new opportunities for HIV prevention education and counseling. Previous research has demonstrated that peer-delivered messaging has the potential to increase the interpretation and uptake of HIV prevention information by PWUD, providing value above POCT alone [25,26].

While there were few differences in characteristics among those who agreed and did not agree to HIV POCT, a few key findings emerged. There was high uptake of our community-based testing model among PWUD at high risk of HIV infection, including those who use injection drugs [27] and those reporting drug use while incarcerated [28]. These findings corroborate those of a Baltimore study that found high opt-in rates for onsite rapid HIV testing at probation and parole offices [10]. In our study, testing followed an hour-long interview, and honoraria were provided regardless of whether or not testing occurred, thus testing rates likely reflect a strong desire to be tested among individuals who have previously been incarcerated. However, low agreement for testing among female participants and those involved in sex work suggest the need for more targeted approaches to reach populations who may face multiple sources of stigma and experience increased barriers to accessing HIV testing and treatment services [29]. More specialized approaches, including female only services [29,30], should be explored to better reach these groups.

There are several limitations to our study. First, we used purposive sampling, which allowed us to target recruitment towards those facing multiple and intersecting oppressions among the study participants. However, our findings may not be applicable to all populations of PWUD. Second, characteristics are based on self-report to highly sensitive questions, which may have contributed to social desirability bias and an underreporting of high-risk practices. Third, it is possible that those who declined testing did so not because of the absence or presence of characteristics found to be associated with uptake of testing, but because they were aware of their positive status or had very recent testing, which was not fully elicited by our study. It is also possible that characteristics of testers other than peer or student status influenced uptake. For example, peers tended to be older and male, whereas medical students were younger and female. Participants were provided an option for who would conduct the test when possible, but availability may have also contributed to the ultimate uptake of HIV POCT. Finally, only one new reactive POCT was determined among participants. It is possible that our recruited population was already served by other testing and care services, or that HIV rates may be higher among those who did not agree to testing.

As we move towards scaling up HIV testing opportunities among at-risk groups, there is a need to develop novel models of community-based testing that draw on the strengths of peer involvement to reach individuals who may not seek testing and treatment in conventional health care settings. The PROUD study has shown high uptake of community-based and peer-administered HIV POCT among PWUD at highest risk of HIV acquisition. Future community and peer-based approaches should be implemented towards specific at-risk communities, including women and those involved in sex work, who may face challenges in accessing conventional clinic-based HIV-testing and treatment services.

Acknowledgments

We would like to thank everyone who provided their expertise and time to this project, particularly our PROUD Community Advisory Committee members: Kelly F., Chris D., Dan M., Rick S., Tyler P., Hana D., Alana M., Tarah H., Caleb C., Fred C., Sean L., June C., Christine L., and Gilles D. (lead author for the committee: Mark W. Tyndall (Mark.Tyndall@bccdc.ca)); Ottawa Public Health for their support of the HIV POCT component of the project; our medical student volunteers; and all of our community partners. We would also like to thank all of the individuals who participated in the study.

Data Availability

Data pertaining to people who use drugs are highly sensitive in nature given the criminalization of drug use in the Canadian context. We are therefore not able to make the database publicly available in order to fully protect participants’ confidentiality. To achieve access to the data used in this paper, interested researchers should contact Dr. Claire Kendall at ckendall@uottawa.ca. Data are from the PROUD study whose authors may be contacted at ckendall@uottawa.ca.

Funding Statement

Funding has been received for this work from the Canadian Institutes of Health Research (FRN 134048; http://www.cihr-irsc.gc.ca/e/193.html), the Ontario HIV Treatment Network (http://www.ohtn.on.ca), and The Ottawa Hospital, Department of Medicine and Division of Infectious Diseases (https://www.ottawahospital.on.ca). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Grigoryan A, Hall H, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996–2004. PLoS ONE 2009;4:e4445 10.1371/journal.pone.0004445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Montaner JSG, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006;368:531–536. 10.1016/S0140-6736(06)69162-9 [DOI] [PubMed] [Google Scholar]
  • 3.World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO; 2013. http://www.who.int/hiv/pub/guidelines/arv2013/en/ (Accessed 12 Feb 2015). [PubMed] [Google Scholar]
  • 4.Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 2007;46(Suppl 1):S3–8. [DOI] [PubMed] [Google Scholar]
  • 5.Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, et al. Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS 2010;24:1929–1935. 10.1097/QAD.0b013e32833af85d [DOI] [PubMed] [Google Scholar]
  • 6.Marwick N, Ti L, Callon C, Feng C, Wood E, Kerr T. Willingness to engage in peer-delivered HIV voluntary counselling and testing among people who inject drugs in a Canadian setting. J Epidemiol Community Health 2014;68:675–678. 10.1136/jech-2013-203707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wood E, Kerr T, Tyndall MW, Montaner JS. A review of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008;22:1247–56. 10.1097/QAD.0b013e3282fbd1ed [DOI] [PubMed] [Google Scholar]
  • 8.Bowles KE, Clark HA, Tai E, Sullivan PS, Song B, Tsang J, et al. Implementing rapid HIV testing in outreach and community settings: results from an advancing HIV prevention demonstration project conducted in seven US cities. Public Health Reports 2008;123:78–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ruutel K, Ustina V, Parker RD. Piloting HIV rapid testing in community-based settings in Estonia. Scandinavian Journal of Public Health 2012;40:629–633. 10.1177/1403494812458987 [DOI] [PubMed] [Google Scholar]
  • 10.Gordon MS, Kinlock TW, McKenzie M, Wilson ME, Rich JD. Rapid HIV Testing for Individuals on Probation/Parole: Outcomes of an Intervention Trial. AIDS Behav 2013;17:2022–2030. 10.1007/s10461-013-0456-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Champenois K, Le Gall J-M, Jacquemin C, Jean S, Martin C, Rios L, et al. ANRS-COM’TEST: Description of a community-based HIV testing intervention in non-medical settings for men who have sex with men. BMJ Open 2012;2:e000693 10.1136/bmjopen-2011-000693 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Latkin CA. Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users' networks. Public Health Reports 1998;113:151–159. [PMC free article] [PubMed] [Google Scholar]
  • 13.Tobin KE, Kuramoto SJ, Davey-Rothwell MA, Latkin CA. The STEP into action study: a peer-based, personal risk network focused HIV prevention intervention with injection drug users in Baltimore, Maryland. Addiction 2011;106:366–375. 10.1111/j.1360-0443.2010.03146.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rhodes T. The risk environment: a framework for understanding and reducing drug-related harm. Int J Drug Pol 2002;13:85–94. [Google Scholar]
  • 15.Davidson P, Page K. Research participation as work: comparing the perspectives of researchers and economically marginalized populations. Am J Public Health 2012;102:1254–1259. 10.2105/AJPH.2011.300418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Adam BD. Epistemic fault lines in biomedical and social approaches to HIV prevention. Journal of International AIDS Society 2011;14(Suppl 2):S2 http://www.jiasociety.org/content/14/S2/S2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Pujol F, Meulbroek M, Saz J, Taboada H, Montilla E, Ditzel E, et al. BCN checkpoint: three-year experience (2007–2009) of a community based centre for MSM in Barcelona (Spain) shows high effectiveness in HIV detection. International AIDS Conference. Vienna, Austria: International AIDS Society 2010:18–23.
  • 18.Yan H, Zhang R, Wei C, Li J, Xu J, Yang H, et al. A peer-led, community-based rapid HIV testing intervention among untested Men Who Have Sex With Men in China: an operational model for expansion of HIV testing and linkage to care. Sex Transm Infect 2014;90:388–393. 10.1136/sextrans-2013-051397 [DOI] [PubMed] [Google Scholar]
  • 19.Tolson M. Seek and Treat to Optimally Prevent (S.T.O.P.)HIV/AIDS: Community Engagement Report. Vancouver: Vancouver Coastal Health; 2011.
  • 20.Ottawa Public Health. Substance Misuse in Ottawa: Technical Report. March 2013. Ottawa (ON): Ottawa Public Health; 2013.
  • 21.Ottawa Public Health. Overdoes and HIV and hepatitis C infection among people in Ottawa who use drugs. January 2014. Ottawa (ON): Ottawa Public Health; 2014. [Google Scholar]
  • 22.Remis R, Swantee C, Liu J. Report on HIV/AIDS in Ontario 2009. June 2012. http://www.ohemu.utoronto.ca/doc/PHERO2009_report_final.pdf (Accessed 12 Feb 2015).
  • 23.Lazarus L, Shaw A, LeBlanc S, Martin A, Marshall Z, Weersink K, et al. Establishing a community-based participatory research partnership among people who use drugs in Ottawa: the PROUD cohort study. Harm Reduction Journal 2014;11:26 10.1186/1477-7517-11-26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Walter SD. Choice of effect measure for epidemiological data. J Clin Epidemiol 2000;53(9):931–9. [DOI] [PubMed] [Google Scholar]
  • 25.Coupland H, Maher L, Enriquez J, Le K, Pacheco V, Pham A, et al. Clients or colleagues? Reflections on the process of participatory action research with young injecting drug users. Int J Drug Pol 2005;16:191–198. [Google Scholar]
  • 26.Dickson-Gomez J, Weeks M, Martinez M, Convey M. Times and places: process evaluation of a peer-led HIV prevention intervention. Subst Use Misuse 2006;41:669–690. 10.1080/10826080500411403 [DOI] [PubMed] [Google Scholar]
  • 27.Lauplans KB, Embril JM. Reducing the adverse impact of injection drug use in Canada. Can J Infect Dis Med Microbiol 2012;23:106–107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kouyoumdjian F, Schuler A, Matheson FI, Hwang SW. Health status of prisoners in Canada Narrative review. Canadian Family Physician 2016;62(3):215–22. [PMC free article] [PubMed] [Google Scholar]
  • 29.Lazarus L, Deering KN, Nabess R, Gibson K, Tyndall MW, Shannon K. Occupational stigma as a primary barrier to health care for street-based sex workers in Canada. Culture, Health & Sexuality 2012;14:139–150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kim SR, Goldenberg SM, Duff P, Nguyen P, Gibson K, Shannon K. Uptake of a women-only, sex-work-specific drop-in center and links with sexual and reproductive health care for sex workers. International Journal of Gynecology & Obstetrics 2015;128:201–205. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data pertaining to people who use drugs are highly sensitive in nature given the criminalization of drug use in the Canadian context. We are therefore not able to make the database publicly available in order to fully protect participants’ confidentiality. To achieve access to the data used in this paper, interested researchers should contact Dr. Claire Kendall at ckendall@uottawa.ca. Data are from the PROUD study whose authors may be contacted at ckendall@uottawa.ca.


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES